Latest News and Press Releases

-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with...

Norfolk, Va., March 20, 2025 (GLOBE NEWSWIRE) -- Judette Louis, MD, M.P.H., has been named dean of Macon & Joan Brock Virginia Health Sciences Eastern Virginia Medical School at Old Dominion...

Dublin, March 13, 2025 (GLOBE NEWSWIRE) -- The "Ultrasound Image Analysis Software Market by Type, by Product, by Application, by End-User, and By Region" report has been added to ...

Myriad Genetics today announced financial results for its fourth quarter and full-year ended December 31, 2024.

Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGS Net product sales of FILSPARI totaled $50 million in 4Q 2024; $132 million for full...

– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in...

– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment...

-2025 is poised to be a catalyst-rich year with key updates across several programs- -Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25

Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter sNDA...